128 related articles for article (PubMed ID: 28726081)
21. Results of reinduction therapy with paclitaxel and carboplatin in recurrent epithelial ovarian cancer.
Gronlund B; Høgdall C; Hansen HH; Engelholm SA
Gynecol Oncol; 2001 Oct; 83(1):128-34. PubMed ID: 11585424
[TBL] [Abstract][Full Text] [Related]
22. Combination chemotherapy with carboplatin and docetaxel in the treatment of cancers of the ovary and fallopian tube and primary carcinoma of the peritoneum.
Markman M; Kennedy A; Webster K; Peterson G; Kulp B; Belinson J
J Clin Oncol; 2001 Apr; 19(7):1901-5. PubMed ID: 11283121
[TBL] [Abstract][Full Text] [Related]
23. Combined weekly carboplatin and paclitaxel as primary treatment of advanced epithelial ovarian carcinoma.
Safra T; Menczer J; Bernstein RM; Shpigel S; Matcejevsky D; Inbar MJ; Golan A; Grisaru D; Levy T
Gynecol Oncol; 2009 Aug; 114(2):215-8. PubMed ID: 19446318
[TBL] [Abstract][Full Text] [Related]
24. Sequential chemotherapy with carboplatin followed by weekly paclitaxel in advanced ovarian cancer: results of a multicenter phase II study of the northeastern German society of gynecological oncology.
Oskay-Ozcelik G; Chekerov R; Sommer H; Keil E; Einenkel J; Pfisterer J; Lorenz-Schlüter C; Lichtenegger W; Camara O; Sehouli J
Gynecol Oncol; 2010 Mar; 116(3):317-22. PubMed ID: 19959213
[TBL] [Abstract][Full Text] [Related]
25. The influence of sarcopenia on survival and surgical complications in ovarian cancer patients undergoing primary debulking surgery.
Rutten IJ; Ubachs J; Kruitwagen RF; van Dijk DP; Beets-Tan RG; Massuger LF; Olde Damink SW; Van Gorp T
Eur J Surg Oncol; 2017 Apr; 43(4):717-724. PubMed ID: 28159443
[TBL] [Abstract][Full Text] [Related]
26. Weekly paclitaxel and carboplatin (PC-W) for patients with primary advanced ovarian cancer: results of a multicenter phase-II study of the NOGGO.
Sehouli J; Stengel D; Mustea A; Camara O; Keil E; Elling D; Ledwon P; Christiansen B; Klare P; Gebauer G; Schwarz M; Lichtenegger W;
Cancer Chemother Pharmacol; 2008 Feb; 61(2):243-50. PubMed ID: 17393164
[TBL] [Abstract][Full Text] [Related]
27. A paclitaxel-containing chemotherapy does not cause central nervous adverse effects: a prospective study in patients with ovarian cancer.
Mayerhofer K; Bodner-Adler B; Bodner K; Saletu B; Schindl M; Kaider A; Hefler L; Leodolter S; Kainz C
Anticancer Res; 2000; 20(5C):4051-5. PubMed ID: 11268500
[TBL] [Abstract][Full Text] [Related]
28. Sorafenib in combination with carboplatin and paclitaxel as neoadjuvant chemotherapy in patients with advanced ovarian cancer.
Pölcher M; Eckhardt M; Coch C; Wolfgarten M; Kübler K; Hartmann G; Kuhn W; Rudlowski C
Cancer Chemother Pharmacol; 2010 May; 66(1):203-7. PubMed ID: 20204367
[TBL] [Abstract][Full Text] [Related]
29. A pilot study of docetaxel-carboplatin versus paclitaxel-carboplatin in Japanese patients with epithelial ovarian cancer.
Mori T; Hosokawa K; Kinoshita Y; Watanabe A; Yamaguchi T; Kuroboshi H; Kato Y; Yasuda J; Fujita H; Nakata Y; Honjo H
Int J Clin Oncol; 2007 Jun; 12(3):205-11. PubMed ID: 17566844
[TBL] [Abstract][Full Text] [Related]
30. Repetitive high-dose topotecan, carboplatin, and paclitaxel with peripheral blood progenitor cell support in previously untreated ovarian cancer: results of a Phase I study.
Prince HM; Rischin D; Quinn M; Allen D; Planner R; Neesham D; Gates P; Davison J
Gynecol Oncol; 2001 May; 81(2):216-24. PubMed ID: 11330952
[TBL] [Abstract][Full Text] [Related]
31. Randomized phase 3 trial of interferon gamma-1b plus standard carboplatin/paclitaxel versus carboplatin/paclitaxel alone for first-line treatment of advanced ovarian and primary peritoneal carcinomas: results from a prospectively designed analysis of progression-free survival.
Alberts DS; Marth C; Alvarez RD; Johnson G; Bidzinski M; Kardatzke DR; Bradford WZ; Loutit J; Kirn DH; Clouser MC; Markman M;
Gynecol Oncol; 2008 May; 109(2):174-81. PubMed ID: 18314182
[TBL] [Abstract][Full Text] [Related]
32. First-line chemotherapy with weekly paclitaxel and carboplatin for advanced ovarian cancer: a phase I study.
Sehouli J; Stengel D; Elling D; Ortmann O; Blohmer J; Riess H; Lichtenegger W;
Gynecol Oncol; 2002 May; 85(2):321-6. PubMed ID: 11972395
[TBL] [Abstract][Full Text] [Related]
33. Evaluating the total costs of chemotherapy-induced toxicity: results from a pilot study with ovarian cancer patients.
Calhoun EA; Chang CH; Welshman EE; Fishman DA; Lurain JR; Bennett CL
Oncologist; 2001; 6(5):441-5. PubMed ID: 11675522
[TBL] [Abstract][Full Text] [Related]
34. Clinical trial and pharmacokinetic study of combination paclitaxel and carboplatin in patients with epithelial ovarian cancer.
Yamamoto R; Kaneuchi M; Nishiya M; Todo Y; Takeda M; Okamoto K; Negishi H; Sakuragi N; Fujimoto S; Hirano T
Cancer Chemother Pharmacol; 2002 Aug; 50(2):137-42. PubMed ID: 12172979
[TBL] [Abstract][Full Text] [Related]
35. Phase II study of paclitaxel and valspodar (PSC 833) in refractory ovarian carcinoma: a gynecologic oncology group study.
Fracasso PM; Brady MF; Moore DH; Walker JL; Rose PG; Letvak L; Grogan TM; McGuire WP
J Clin Oncol; 2001 Jun; 19(12):2975-82. PubMed ID: 11408492
[TBL] [Abstract][Full Text] [Related]
36. Weekly carboplatin with paclitaxel compared to standard three-weekly treatment in advanced epithelial ovarian carcinoma--a retrospective study.
Safra T; Shamai S; Greenberg J; Veizman A; Shpigel S; Matcejevsky D; Pelles S; Inbar M; Levy T; Grisaru D
Gynecol Oncol; 2014 Jan; 132(1):18-22. PubMed ID: 23850468
[TBL] [Abstract][Full Text] [Related]
37. Is chemotherapy-induced neutropenia a prognostic factor in patients with ovarian cancer?
Kim JJ; Park JY; Kim DY; Kim JH; Kim YM; Nam JH; Kim YT
Acta Obstet Gynecol Scand; 2010 May; 89(5):623-8. PubMed ID: 20423275
[TBL] [Abstract][Full Text] [Related]
38. Dose-escalated paclitaxel in 1-hour infusion with a fixed dose of cisplatin in previously untreated advanced ovarian cancer: a phase II trial of the Spanish Group for Ovarian Cancer.
Cervantes A; Mendiola C; del Campo JM; Massuti B; Casado A; Escobedo A; Moyano A; Ojeda B; Poveda A; Benito D
Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-40-S15-43. PubMed ID: 9346221
[TBL] [Abstract][Full Text] [Related]
39. Paclitaxel combined with carboplatin in the first-line treatment of advanced ovarian cancer: a phase I trial.
Meerpohl HG; du Bois A; Luck HJ; Kühnle H; Möbus V; Kreienberg R; Bauknecht T; Köchli O; Bochtler H; Diergarten K
Semin Oncol; 1997 Feb; 24(1 Suppl 2):S2-17-S2-22. PubMed ID: 9045330
[TBL] [Abstract][Full Text] [Related]
40. Psychometric evaluation of two scales assessing functional status and peripheral neuropathy associated with chemotherapy for ovarian cancer: a gynecologic oncology group study.
Almadrones L; McGuire DB; Walczak JR; Florio CM; Tian C
Oncol Nurs Forum; 2004 May; 31(3):615-23. PubMed ID: 15146227
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]